You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
小智港美股早報 | 2月9日

昨夜行情

昨夜行情

大公司頭條

官宣炒掉CEO、裁員2800人之後,派樂騰的股價起飛了。

強生悄悄暫停生產新冠疫苗。

蘋果計劃在iPhone上推出“點擊支付”功能。

“品牌大師”轉型計劃初步起效,哈雷摩託交出驚豔四季報。

輝瑞四季度營收遜於預期,預計今年疫苗口服藥將合砍540億美元。

藥明生物:公司正積極採取臨時措施要求美國商務部將子公司從未經覈實名單移除。

廣汽集團:1月汽車銷量23.72萬輛,同比增長9.16%。

火幣科技擬認購1000萬美元基金合夥權益。

諾誠健華-B:若幹股東自願作出禁售承諾。

萬科企業1月合同銷售額356億元。

脫水研報

大摩重申藥明生物爲今年首選股,公司2021年純利預增逾98%,盈喜勝預期。

小摩預期,ADS註冊和疲軟的線上消費將爲阿裏巴巴-SW股價短期內帶來壓力。

美銀證券予統一企業中國及康師傅控股“買入”評級,方便麪業或迎近10年首次大幅加價。

交銀國際預期,騰訊控股業績於2022年下半年好轉,重點關注新業務變現及對傳統業務數字化帶來長期增量。

大摩:予好市多“增持”評級,目標價爲560美元。

大摩:將Snowflake評級由“持股觀望”上調至“增持”,目標價由344美元上調至390美元。

Stifel:予Peloton“買入”評級,目標價40美元。

Wedbush:予蘋果“跑贏大盤”評級,目標價200美元。

Truist:予Peloton“持有”評級,目標價爲68美元。

Wedbush:予耐克“跑贏大盤”評級,目標價爲185美元。

熱點公告

和譽-B:和譽醫藥完成ABSK011與抗PD-L1抗體聯合用藥臨牀II期試驗的首例患者給藥。

宏觀頭條

美股轉漲掙脫Meta影響,中概強勢反彈,美債收益率逾兩年新高,原油加速回落,倫鋁高漲。

中國央行等多部門印發《金融標準化“十四五”發展規劃》:推進法定數字貨幣標準研製、金融科技標準建設。

美將33家中國實體列入出口管制“未經驗證清單”,商務部迴應;藥明生物:“未經覈實的名單”不是“實體名單”或“黑名單”,公司業務沒有受到影響。

人民日報評論:正確認識和把握資本的特性和行爲規律。

今年上海個人住房房產稅稅率分界線更新:81948元/平米。

中國第三金!18歲的谷愛凌創造歷史!手握20多個代言,背後品牌賺了。

最近私募有點難:實控人意外離世,大佬旗下產品觸及止損線,逾百隻處清倉邊緣。

美國願與伊朗就伊核談判達成協議,國際原油盤中跌3%;美官方大幅上調今年原油預期價,明年美國產油或創新高。

交易員縮減美元押注,因美聯儲加息前景危及美國經濟增長。

今日招股

美華國際醫療(MHUA)正在招股,招股價10.50~10.50美元,入場費10.50美元。

清晰醫療(01406)正在招股,招股價1.60~3.00港元,入場費3787.80港元。

匯通達網絡(09878)正在招股,招股價43.00~48.00港元,入場費4848.38港元。

uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account